Drug Approval | June 23, 2022
Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
The revamped Ayushman Bharat Health Account (ABHA) mobile application offers added functionalities and a new User Interface (UI)
Risk management plans can serve as a safeguard, helping manufacturers prepare for and respond to hazards that could lead to drug supply disruptions and shortages
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
In the UK, Bartec has been synonymous with Mediso products for 18 years, proof of a successful partnership
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Subscribe To Our Newsletter & Stay Updated
